Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates

Abstract excerpt

Lassa virus (LASV) is a World Health Organization (WHO) priority pathogen that causes high morbidity and mortality. Recently, we showed that a combination of three broadly neutralizing human monoclonal antibodies known as Arevirumab-3 (8.9F, 12.1F, 37.2D) based on the lineage IV Josiah strain protected 100% of cynomolgus macaques against heterologous challenge with lineage II and III strains of LASV when therapy...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacillus and Francisella bacterial research
• Share to SARS-CoV-2 and COVID-19 Research
• Share to Viral Infections and Outbreaks Research